Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, \>/= 18 years of age
Participants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesions
Histopathologic confirmation that at least one of the three target lesions is basal cell carcinoma
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Adequate renal and hepatic function and hematopoietic capacity
Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatment
Male participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatment
You may not be if
Inability or unwillingness to swallow capsules
Pregnant or breastfeeding women
Any metastatic basal cell carcinoma
Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to have medical contraindications to surgery
Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study
Known or suspected alcohol abuse
One of the following known rare hereditary conditions: galactose intolerance, primary hypolactasia or glucose-galactose malabsorption
Clareo Health | A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
